Proposing the Financial Invention Review Board: Part 1, powers
By: David A. Smith
Before we unleash a new financial drug on the world, might it require some clinical field trials? That question lies behind a fascinating Harvard Business Review op-ed by of all people and places, Lawrence Candell from MIT’s Lincoln Laboratories:
What can you do in a democracy when you rely on the private sector [...]
